<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986114</url>
  </required_header>
  <id_info>
    <org_study_id>D1002002</org_study_id>
    <secondary_id>JapicCTI-132319</secondary_id>
    <secondary_id>2013-003039-31</secondary_id>
    <nct_id>NCT01986114</nct_id>
  </id_info>
  <brief_title>A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.</brief_title>
  <official_title>A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the long-term efficacy and safety of SM-13496 in patients with bipolar I
      disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to evaluate the long-term efficacy and safety of SM-13496 (20-120
      mg/day) in patients with bipolar I disorder.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2014</start_date>
  <completion_date type="Actual">February 17, 2018</completion_date>
  <primary_completion_date type="Actual">February 8, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)</measure>
    <time_frame>28, 52 weeks</time_frame>
    <description>The number and percentage of subjects with at least one adverse event and adverse drug reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score</measure>
    <time_frame>Baseline, 52 weeks and each month</time_frame>
    <description>Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.
The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score.</measure>
    <time_frame>Baseline, 52 weeks and each month</time_frame>
    <description>YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder.
The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>The number and percentage of subjects who experienced recurrence/relapse of any mood event from clinical stability of bipolar disorder.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>SM-13496 20-120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily orally SM-13496 20-120 mg flexibly dosed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM-13496</intervention_name>
    <arm_group_label>SM-13496 20-120mg</arm_group_label>
    <other_name>Lurasidone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who completed the D1002001 study

        ・Patients who completed the D1002001 study and who are considered by the investigator to be
        eligible and without safety concerns.

        Patients who did not participate in the D1002001 study

          -  Patients who were fully informed of and understand the objectives, procedures, and
             possible benefits and risks of the study and who provided written voluntary consent to
             participate in the study.

          -  Outpatients aged 18 through 74 years at the time of consent

          -  Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode manic,
             hypomanic, or mixed with or without rapid cycling disease course (≥ 4 episodes of mood
             disturbance, but &lt; 8 episodes in the previous 12 months prior to screening).

        Exclusion Criteria:

          -  Patients with imminent risk of suicide or injury to self, others, or property.

          -  Patients who are otherwise considered ineligible for the study by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Drug Development Division</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippoon Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan 68 sites</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lithuania 3 sites</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malaysia 5 sites</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippines 5 sites</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russia 19 sites</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slovakia 5 sites</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taiwan 8 sites</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukraine 9 sites</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <results_first_submitted>May 19, 2019</results_first_submitted>
  <results_first_submitted_qc>May 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01986114/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01986114/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>495 represents the total number of subjects who were treated with study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SM-13496 20-120mg</title>
          <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="495"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="339"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population-received at least one dose of study medication</population>
      <group_list>
        <group group_id="B1">
          <title>SM-13496 20-120mg</title>
          <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="12.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)</title>
        <description>The number and percentage of subjects with at least one adverse event and adverse drug reaction</description>
        <time_frame>28, 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 20-120mg (Overall, 28 Weeks)</title>
            <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 28 weeks</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 20-120mg (Japan, 52 Weeks)</title>
            <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)</title>
          <description>The number and percentage of subjects with at least one adverse event and adverse drug reaction</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score</title>
        <description>Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.
The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.</description>
        <time_frame>Baseline, 52 weeks and each month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 20-120mg (Overall, 28 Weeks)</title>
            <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 28 weeks</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 20-120mg (Japan, 52 Weeks)</title>
            <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Long Term Study Baseline to LOCF Endpoint in the Montgomery-Asberg Depression Rating Scale (MADRS) Score</title>
          <description>Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.
The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="12.09"/>
                    <measurement group_id="O2" value="1.1" spread="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score.</title>
        <description>YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder.
The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.</description>
        <time_frame>Baseline, 52 weeks and each month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 20-120mg (Overall, 28 Weeks)</title>
            <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 28 weeks</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 20-120mg (Japan, 52 Weeks)</title>
            <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Long Term Study Baseline to LOCF Endpoint in the Young Mania Rating Scale (YMRS) Total Score.</title>
          <description>YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder.
The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.
The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.54"/>
                    <measurement group_id="O2" value="-2.0" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.</title>
        <description>The number and percentage of subjects who experienced recurrence/relapse of any mood event from clinical stability of bipolar disorder.</description>
        <time_frame>Baseline to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 20-120mg (Overall, 28 Weeks)</title>
            <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 28 weeks</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 20-120mg (Japan, 52 Weeks)</title>
            <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.</title>
          <description>The number and percentage of subjects who experienced recurrence/relapse of any mood event from clinical stability of bipolar disorder.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 28 weeks (outside Japan) and 52 weeks (Japan).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SM-13496 20-120mg (Overall, 28 Weeks)</title>
          <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 28 weeks</description>
        </group>
        <group group_id="E2">
          <title>SM-13496 20-120mg (Japan, 52 Weeks)</title>
          <description>once daily orally
SM-13496 (lurasidone HCl): SM-13496 20-120mg flexibly dosed up to 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="495"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="495"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="495"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="495"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="495"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="35" subjects_at_risk="495"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="495"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="495"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="63" subjects_affected="51" subjects_at_risk="495"/>
                <counts group_id="E2" events="72" subjects_affected="53" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="495"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="104" subjects_affected="91" subjects_at_risk="495"/>
                <counts group_id="E2" events="64" subjects_affected="60" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="495"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="46" subjects_affected="37" subjects_at_risk="495"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="43" subjects_affected="34" subjects_at_risk="495"/>
                <counts group_id="E2" events="25" subjects_affected="15" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="44" subjects_affected="41" subjects_at_risk="495"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research</name_or_title>
      <organization>Sumitomo Dainippon Pharmaceutical</organization>
      <phone>+81-3-5159-2519</phone>
      <email>cc@ds-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

